SCHEMBL2144249

SCHEMBL2144249

CNc1nccc(N)c1Cc1ccc(OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
CYP2D6 P10635 1/20 0.51
ATM Q13315 1/20 0.51
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.42
LTA4H P09960 2/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
PDE10A Q9Y233 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PTGIR P43119 1/20 0.40
KDR P35968 2/20 0.39
DYRK1A Q13627 1/20 0.39
SYK P43405 1/20 0.39
MPO P05164 1/20 0.39
NR3C2 P08235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28054249 0.83 ALDH1A1 (0.59) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL1743766 0.74 PDE3B (0.54) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL23045757 0.73 ALDH1A1 (0.58) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL31599804 0.72 LMNA (0.45) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
Ammonia Solution, Strong SCHEMBL25279198 0.72 ALDH1A1 (0.56) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL8097615 0.71 ALDH1A1 (0.65) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL2981296 0.71 ALDH1A1 (0.56) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL7522555 0.70 ALDH1A1 (0.68) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL2984769 0.70 ALDH1A1 (0.54) ALDH1A1CYP2D6ATMLMNASMN1; SMN2
SCHEMBL29433996 0.70 ALDH1A1 (0.58) ALDH1A1CYP2D6ATMLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344494-B1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARM LLC (US) 2016-04-20 EP disclosed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 US disclosed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 ALDH1A1 1694/4885CYP2D6 1459/4885ATM 39/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 ALDH1A1 1694/4885CYP2D6 1459/4885ATM 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.